Holen Sie sich die Stockscreener-App
2.10
9.87%
-0.23
Schlusskurs vom Vortag:
$2.33
Offen:
$2.24
24-Stunden-Volumen:
1.44M
Relative Volume:
1.24
Marktkapitalisierung:
$183.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-95.90M
KGV:
-1.5909
EPS:
-1.32
Netto-Cashflow:
$-79.09M
1W Leistung:
-28.08%
1M Leistung:
-40.17%
6M Leistung:
-74.61%
1J Leistung:
-61.75%
1-Tages-Spanne:
$2.08
$2.29
1-Wochen-Bereich:
$2.08
$2.88
52-Wochen-Spanne:
$2.08
$11.40
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Firmenname
Terns Pharmaceuticals Inc
Sektor
Branche
Telefon
650-525-5535 EXT.101
Adresse
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Vergleichen Sie TERN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
2.10 | 183.33M | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2024-10-31 | Eingeleitet | Oppenheimer | Outperform |
| 2023-06-22 | Eingeleitet | Mizuho | Buy |
| 2023-06-07 | Eingeleitet | Jefferies | Buy |
| 2023-05-31 | Eingeleitet | ROTH MKM | Buy |
| 2023-05-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-14 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-02-07 | Eingeleitet | UBS | Buy |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-09-14 | Fortgesetzt | Goldman | Buy |
| 2021-03-02 | Eingeleitet | Cowen | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Buy |
| 2021-03-02 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Terns Pharmaceuticals Inc Aktie (TERN) Neueste Nachrichten
Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN) - Yahoo Finance
Terns pharmaceuticals chief medical officer sells $2,365 in stock - Investing.com Australia
Terns Pharmaceuticals Reports Inducement Grant To New Employees Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Terns Pharmaceuticals stock hits 52-week low at $2.5 By Investing.com - Investing.com South Africa
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Terns Pharmaceuticals Attracts Top Talent with 611,000-Share Equity Package - Stock Titan
Terns Pharmaceuticals stock hits 52-week low at $2.5 - Investing.com India
Terns Pharmaceuticals stock hits 52-week low at $4.16 - MSN
Insider Purchases Worth US$5.17m See Losses As Terns Pharmaceuticals Market Value Drops To US$255m - simplywall.st
HighTower Advisors LLC Invests $468,000 in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Charles Schwab Investment Management Inc. Raises Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives $18.30 Average Price Target from Analysts - Defense World
Terns Pharmaceuticals Reports 2024 Progress and Outlook - TipRanks
Terns Pharmaceuticals stock hits 52-week low at $3.08 By Investing.com - Investing.com South Africa
All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy - MSN
Terns Pharmaceuticals stock hits 52-week low at $3.08 - Investing.com
Bank of New York Mellon Corp Raises Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Connor Clark & Lunn Investment Management Ltd. Boosts Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals (NASDAQ:TERN) Earns Market Perform Rating from William Blair - Defense World
Terns Pharmaceuticals Inc. (TERN) reports earnings - Quartz
Terns Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Terns Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates - GlobeNewswire
Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential By Investing.com - Investing.com South Africa
Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential - Investing.com
Terns Pharmaceuticals stock hits 52-week low at $3.27 By Investing.com - Investing.com Australia
Terns Pharmaceuticals stock hits 52-week low at $3.27 - Investing.com India
This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street - sharewise
Rhumbline Advisers Acquires 13,479 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
3 Growth Stocks with Exciting Potential - The Globe and Mail
Chronic Myeloid Leukemia Market Expected to Experience Major - openPR
Public market insider buying at Paramount Resources (POU) - The Globe and Mail
Terns Pharmaceuticals (TERN) Projected to Post Quarterly Earnings on Thursday - Defense World
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of “Moderate Buy” from Brokerages - The AM Reporter
Terns Pharmaceuticals stock hits 52-week low at $3.54 - Investing.com India
Terns Pharmaceuticals stock hits 52-week low at $3.54 By Investing.com - Investing.com South Africa
Brokerages Set Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Target Price at $18.30 - Defense World
William Blair Initiates Coverage on Terns Pharmaceuticals (NASDAQ:TERN) - Defense World
William Blair Initiates Terns Pharmaceuticals at Market Perform -February 28, 2025 at 08:12 am EST - Marketscreener.com
Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Terns Pharmaceuticals reports progress in clinical trials By Investing.com - Investing.com Australia
New Terns Pharmaceuticals CFO Receives $2.8M Stock Option Package: What's Behind the Compensation? - StockTitan
Finanzdaten der Terns Pharmaceuticals Inc-Aktie (TERN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):